Evidence map›Paper›PMID 22978652›Full record

ArticleBiochemistry2012

A small molecule inhibitor of Pot1 binding to telomeric DNA.

Sarah E Altschuler, Johnny E Croy, Deborah S Wuttke

Open access · greenAbstract read
In one paragraph

Article in Biochemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Telomere Targeting Approaches in Cancer: Beyond Length Maintenance.International journal of molecular sciences · 2022
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sarah E AltschulerDepartment of Chemistry and Biochemistry, University of Colorado, Boulder, Colorado 80309-0215, USA.
Johnny E Croy
Deborah S Wuttke
University of Colorado Boulder · US

Funding

GENETIC MECHANISMS AND REGULATIONT32GM007240 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI HAMPTON, RANDOLPH Y. · 1985 to 2019
$23.8M
Predoctoral Training Molecular BiophysicsT32GM065103 · NIGMS · UNIVERSITY OF COLORADO AT BOULDER · PI FALKE, JOSEPH J · 2002 to 2021
$4.3M
SINGLE STRANDED DNA RECOGNITION IN TELOMERESR01GM059414 · NIGMS · UNIVERSITY OF COLORADO AT BOULDER · PI WUTTKE, DEBORAH S. · 1999 to 2015
$3.7M
Development of a HTS Assay Targeting End Protection of TelomeresR21NS059370 · NINDS · UNIVERSITY OF COLORADO · PI WUTTKE, DEBORAH S. · 2007 to 2007
$189k
Structural Analysis of Telomeric DNA Binding to Pot1F32GM071257 · NIGMS · UNIVERSITY OF COLORADO AT BOULDER · PI CROY, JOHNNY E · 2004 to 2006
$134k
Purchase of an Isothermal Titration CalorimeterS10RR026516 · NCRR · UNIVERSITY OF COLORADO · PI BATEY, ROBERT T · 2010 to 2010
$129k
NCRR NIH HHS 1S10 RR026516NCRR NIH HHS S10 RR026516NIGMS NIH HHS F32 GM071257NIGMS NIH HHS GM-059414NIGMS NIH HHS GM065103NIGMS NIH HHS GM-071257NIGMS NIH HHS R01 GM059414NIGMS NIH HHS T32 GM007240NIGMS NIH HHS T32 GM065103NINDS NIH HHS R21 NS059370PHS HHS NSF-059370
6 · The paper itself

Abstract

Chromosome ends are complex structures, consisting of repetitive DNA sequence terminating in an ssDNA overhang with many associated proteins. Because alteration of the regulation of these ends is a hallmark of cancer, telomeres and telomere maintenance have been prime drug targets. The universally conserved ssDNA overhang is sequence-specifically bound and regulated by Pot1 (protection of telomeres 1), and perturbation of Pot1 function has deleterious effects for proliferating cells. The specificity of the Pot1/ssDNA interaction and the key involvement of this protein in telomere maintenance have suggested directed inhibition of Pot1/ssDNA binding as an efficient means of disrupting telomere function. To explore this idea, we developed a high-throughput time-resolved fluorescence resonance energy transfer (TR-FRET) screen for inhibitors of Pot1/ssDNA interaction. We conducted this screen with the DNA-binding subdomain of Schizosaccharomyces pombe Pot1 (Pot1pN), which confers the vast majority of Pot1 sequence-specificity and is highly similar to the first domain of human Pot1 (hPOT1). Screening a library of ∼20 000 compounds yielded a single inhibitor, which we found interacted tightly with sub-micromolar affinity. Furthermore, this compound, subsequently identified as the bis-azo dye Congo red (CR), was able to competitively inhibit hPOT1 binding to telomeric DNA. Isothermal titration calorimetry and NMR chemical shift analysis suggest that CR interacts specifically with the ssDNA-binding cleft of Pot1, and that alteration of this surface disrupts CR binding. The identification of a specific inhibitor of ssDNA interaction establishes a new pathway for targeted telomere disruption.

Indexed as

Amino Acid MotifsCatalytic DomainCombinatorial Chemistry TechniquesCongo RedDNA-Binding ProteinsDNA, Single-StrandedDrug Evaluation, PreclinicalModels, MolecularPeptide FragmentsProtein BindingProtein ConformationProtein FoldingSchizosaccharomyces pombe ProteinsShelterin ComplexSmall Molecule LibrariesTelomereCongo RedDNA-Binding ProteinsDNA, Single-StrandedPeptide Fragmentspot1 protein, S pombeSchizosaccharomyces pombe ProteinsShelterin ComplexSmall Molecule LibrariesTelomere-Binding Proteins

Identifiers

PMID22978652
PMCPMC3514547
OpenAlexW2015979057

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.